Abstract
In the present study, we show that 2‐(2‐hydroxyethylsulfaryl)‐3‐methyl‐1,4‐naphthoquinone, or CPD 5, is a potent growth inhibitor for pancreas cancer cell lines (ID50: 21.4±3.8, 31.8±2.7 and 55.2±4.5 μM for MiaPaCa, Panc‐1 and BxPc3, respectively). It induced protein tyrosine phosphorylation of hepatocyte growth factor (HGF) receptor (c‐Met) or epidermal growth factor receptor (EGFR), which increased progressively to a maximum level at 30 min in Panc‐1 cells. The receptor phosphorylation by CPD 5 was indicated to be functional, since these receptors were found to bind with Grb2 or SOS1 protein. CPD 5 was also suggested to induce phosphorylation of external signal‐regulated kinase (ERK). EGF induced cell proliferation through ERK phosphorylation, since U0126, which is an inhibitor of ERK phosphorylation, abrogated the increase of cyclin D1 by EGF. HGF increased the amount of p27 protein, suggesting that it is associated with cell differentiation. By contrast, U0126 reduced CPD 5‐induced cell death. On two‐dimensional electrophoresis, we found an extra type of phospho‐ERK, and this was completely and selectively abolished by U0126. These results suggest that ERK phosphorylation, especially the extra spot on two‐dimensional gel, is critically associated with CPD 5‐mediated cell death.
Keywords: Extracellular signal‐regulated kinase (ERK), Growth inhibition, Novel vitamin K analog, Phosphorylation, Pancreas cancer cells
Full Text
The Full Text of this article is available as a PDF (151.8 KB).
REFERENCES
- 1. ) Parker , S. L. , Tong , T. , Bolden , S. and Wingo , P. A.Cancer statistics . Cancer , 46 , 5 – 27 ( 1995. ). [DOI] [PubMed] [Google Scholar]
- 2. ) Janes , R. H. , Jr. , Niederhunber , J. E. , Chmiel , J. S. , Winchester , D. P. , Ocwieja , K. C. , Kaenell , J. H. , Clive , R. E. and Menck , H. R.National patterns of care for pancreatic cancer; results of a survey by the commission on cancer . Ann. Surg. , 223 , 261 – 272 ( 1996. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. ) Wanebo , H. J. and Vezeridis , M. P.Pancreatic carcinoma in perspective; a continuing challenge . Cancer , 78 , 580 – 591 ( 1996. ). [DOI] [PubMed] [Google Scholar]
- 4. ) Kerns , J. , Naganathan , S. , Dowd , P. , Finn , F. and Carr , B. I.Thioalkyl derivatives of vitamin K3 and vitamin K3 oxide inhibit growth of Hep 3B and Hep G2 . Bioorg. Chem. , 23 , 101 – 108 ( 1995. ). [Google Scholar]
- 5. ) Ni , R. , Nishikawa , Y. and Carr , B. I.Cell growth inhibition by a novel vitamin K is associated with induction of protein tyrosine phosphorylation . J. Biol. Chem. , 273 , 9906 – 9911 ( 1998. ). [DOI] [PubMed] [Google Scholar]
- 6. ) Nishikawa , Y. , Carr , B. I. , Wang , M. , Kar , S. , Finn , F. , Dowd , P. , Zheng , Z. B. , Kerns , J. and Naganathan , S.Growth inhibition of hepatoma cells by vitamin K and its analogs . J. Biol. Chem. , 270 , 28304 – 28310 ( 1995. ). [DOI] [PubMed] [Google Scholar]
- 7. ) Nishikawa , Y. , Wang , Z. , Kerns , J. , Wilcox , C. S. and Carr , B. I.Inhibition of hepatoma cell growth in vitro by arylating and non‐arylating K vitamin analogs . J. Biol. Chem. , 274 , 34803 – 34810 ( 1999. ). [DOI] [PubMed] [Google Scholar]
- 8. ) Ullrich , A. and Schlesainger , J.Signal transduction by receptors with tyrosine kinase activity . Cell , 61 , 203 – 212 ( 1990. ). [DOI] [PubMed] [Google Scholar]
- 9. ) Favata , M. F. , Horiuchi , K. Y. , Manos , E. J. , Daulerio , A. J. , Stradley , D. A. and Feeser , W. S.Identification of a novel inhibitor of mitogen activated protein kinase kinase . J. Biol. Chem. , 273 , 18623 – 18628 ( 1998. ). [DOI] [PubMed] [Google Scholar]
- 10. ) Blackstock , A. W. , Cox , A. D. and Tepper , T. G.Treatment of pancreatic cancer: current limitations, future possibilities . Oncology , 10 , 301 – 307 ( 1996. ). [PubMed] [Google Scholar]
- 11. ) Bottaro , D. P. , Rubin , J. S. , Faletto , D. L. , Chan , A. M. L. , Kmiecik , T. E. , Vande‐Woude , G. F. and Aaronson , S. A.Identification of the hepatocyte growth factor receptor as the c‐met proto‐oncogene product . Science , 251 , 802 – 804 ( 1991. ). [DOI] [PubMed] [Google Scholar]
- 12. ) Rong , S. , Bodescot , M. , Blair , D. , Dunn , J. , Nakamura , T. , Mizuno , K. , Park , M. , Chan , A. , Aaronson , S. and Vande‐Woude , G. F.Tumorigenicity of the Met protooncogene and the gene for hepatocyte growth factor . Mol. Cell. Biol. , 12 , 5152 – 5158 ( 1992. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. ) Sakata , H. , Takayama , H. , Sharp , R. , Rubin , J. S. , Merlino , G. and LaRochelle , W. J.Hepatocyte growth factor scatter factor overexpression induces growth, abnormal development, and tumor formation in transgenic mouse livers . Cell Growth Differ. , 7 , 1513 – 1523 ( 1996. ). [PubMed] [Google Scholar]
- 14. ) Saitoh , K. , Takahashi , H. , Sawada , N. and Parsons , P. G.Detection of the c‐Met protooncogene product in normal skin and tumors of melanocytic origin . J. Pahol. , 174 , 191 – 199 ( 1994. ). [DOI] [PubMed] [Google Scholar]
- 15. ) Tajima , H. , Matsumoto , K. and Nakamura , T.Hepatocyte growth factor has potent anti‐proliferative activity in various tumor cell lines . FEBS Lett. , 291 , 229 – 232 ( 1991. ). [DOI] [PubMed] [Google Scholar]
- 16. ) Shiota , G. , Rhoads , D. B. , Wang , T. C. , Nakamura , T. and Schmit , E. V.Hepatocyte growth factor inhibits growth of hepatocellular carcinoma cells . Proc. Natl. Acad. Sci. USA , 89 , 271 – 278 ( 1992. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. ) Gill , N. G. and Lazar , C. S.Increased phosphotyrosine content and inhibition of proliferation in EGF‐treated A431 cells . Nature , 293 , 305 – 307 ( 1981. ). [DOI] [PubMed] [Google Scholar]
- 18. ) Gross , M. E. , Zorbas , M. A. , Daniels , Y. J. , Garcia , R. , Gallick , G. E. , Olive , M. , Brattain , M. G. , Boman , B. M. and Yeoman , L. C.Cellular growth response to epidermal growth factor in colon carcinoma cells with adenomatous polyposis patient . Cancer Res. , 51 , 1452 – 1459 ( 1991. ). [PubMed] [Google Scholar]
- 19. ) Clark , S. G. , Stern , M. J. and Horvitz , H. R.C. elegans cell‐signaling gene SEM‐5 encodes a protein with SH2 and SH3 domains . Nature , 356 , 340 – 344 ( 1992. ). [DOI] [PubMed] [Google Scholar]
- 20. ) Skolnik , E. Y. , Batzer , A. , Li , N. , Lee , C. H. , Lowenstein , E. , Mohammaon , M. , Margolis , B. and Schlessinger , J.The function of Grb2 in linking the insulin‐receptor to Ras signaling pathway . Science , 260 , 1953 – 1955 ( 1993. ). [DOI] [PubMed] [Google Scholar]
- 21. ) Chardin , P. , Camonis , J. H. , Gale , N. W. , Van‐Aelst , L. , Schlessinger , J. , Wigler , M. H. and Bar‐Sagi , D.Human SOS 1—a guanine nucleotide exchange factor for Ras that binds to Grb2 . Science , 260 , 1338 – 1343 ( 1993. ). [DOI] [PubMed] [Google Scholar]
- 22. ) Chen , Y. R. , Meyer , C. F. and Tan , T. H.Persistent activation of c‐Jun N‐terminal kinase 1 (JNK1) in gamma radiation‐induced apoptosis . J. Biol. Chem. , 271 , 631 – 634 ( 1996. ). [DOI] [PubMed] [Google Scholar]
- 23. ) Verheij , M. , Bose , R. , Lin , X. H. , Yao , B. , Jarvis , W. D. , Grant , S. , Birrer , M. J. , Szabo , E. , Zon , L. I. , Halmovitz‐Friedman , A. , Funks , Z. and Kolesnick , R. N.Requirement for ceramide‐initiated SAPK/JNK signalling in stressinduced apoptosis . Nature , 380 , 75 – 79 ( 1996. ). [DOI] [PubMed] [Google Scholar]
- 24. ) Pages , G. , Lenormand , P. , Lallemain , G. , Chamband , J. C. , Meloche , S. and Ponyssegur , J.Mitogen activated protein kinases p42 and p44 are required for fibroblast proliferation . Proc. Natl. Acad. Sci. USA , 90 , 8319 – 8323 ( 1993. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. ) Marshall , C. J.Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal‐regulated kinase activation . Cell , 80 , 179 – 185 ( 1995. ). [DOI] [PubMed] [Google Scholar]
- 26. ) Perez‐Juste , G. and Aranda , A.The cyclin‐dependent kinase inhibitor p27 is involved in thyroid hormone‐mediated neuronal differentiation . J. Biol. Chem. , 274 , 5026 – 5031 ( 1999. ). [DOI] [PubMed] [Google Scholar]
- 27. ) DiRenzo , M. F. , Poulsom , R. , Olovero , M. , Comglio , P. M. and Lemoine , N. R.Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer . Cancer Res. , 55 , 1129 – 1138 ( 1995. ). [PubMed] [Google Scholar]
- 28. ) Xia , Z. , Dickens , M. , Raingeaud , J. , Davis , R. J. and Greenberg , M. E.Opposing effects of ERK and JNK‐p38 MAP kinases on apoptosis . Science , 270 , 1326 – 1331 ( 1995. ). [DOI] [PubMed] [Google Scholar]
- 29. ) Leppa , S. , Saffrich , R. , Ansorge , W. and Bohmann , D.Differential regulation of c‐Jun by ERK and JNK during PC12 cell differentiation . EMBO J. , 17 , 4404 – 4413 ( 1998. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. ) Pumiglia , K. M. and Decker , S. J.Cell cycle arrest mediated by the MEK/mitogen‐activated protein kinase pathway . Proc. Natl. Acad. Sci. USA , 94 , 448 – 452 ( 1997. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. ) Zhu , L. , Yu , X. , Akatsuka , Y. , Cooper , J. A. and Anasetti , C.Role of mitogen‐activated protein kinases in activationinduced apoptosis of T cells . Immunology , 97 , 26 – 35 ( 1999. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. ) Brink , M. R. M. , Kapeller , R. , Pratt , J. C. , Chang , J. and Burakoff , S. J.The extracellular signal‐regulated kinase pathway is required for activation‐induced cell death of T cell . J. Biol. Chem. , 274 , 11178 – 11185 ( 1999. ). [DOI] [PubMed] [Google Scholar]